Avalo Therapeutics Inc.
NASDAQ · AVTX·Wayne, PA·Small-cap·Phase 2
Clinical-stage biotech focused on IL-1β-driven immune-mediated inflammatory diseases. Following a 2024 restructuring and AlmataBio acquisition, lead asset abdakibart (AVTX-009) — an anti-IL-1β monoclonal antibody originally developed at Eli Lilly — is in Phase 2 LOTUS for moderate-to-severe hidradenitis suppurativa, with topline expected Q2 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Avalo Corporate Presentation March 2026 | Corporate overview | March 23, 2026 | 21 |